Form 6-K DR REDDYS LABORATORIES For: Jan 06
Tweet
Share
E-mail�
�
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
�
�
FORM 6-K
�
�
Report of Foreign Private Issuer
Pursuant to Rule�13a-16 or 15d-16
of the Securities Exchange Act of 1934
Month of December 2014
Commission File Number � 1-15182
�
�
DR. REDDY�S LABORATORIES LIMITED
(Name of Registrant)
�
�
8-2-337, Road No.�3, Banjara Hills
Hyderabad, Andhra Pradesh 500 034, India
+91-40-4900-2900
(Address of Principal Executive Offices)
�
�
Indicate by check mark whether registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form�20-F��x����������� �Form�40-F���
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation�S-T Rule�101(b)(1):���
Note: Regulation�S-T Rule�101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation�S-T Rule�101(b)(7):���
Note: Regulation�S-T Rule�101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant�s �home country�), or under the rules of the home country exchange on which the registrant�s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant�s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.
Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule�12g3-2(b) under the Securities Exchange Act of 1934.
Yes���������������No� �x
If �Yes� is marked, indicate below the file number assigned to registrant in connection with Rule 12g3-2(b):
Not applicable.
�
�
�
Table of Contents
�
| �� | � | 3 | �� | |
| �� | � | 5 | �� | |
�
2
Dr.�Reddy�s announces the Launch of Valganciclovir Tablets, USP
Hyderabad, India, December�16, 2014
Dr.�Reddy�s Laboratories (NYSE: RDY) announced today that it has launched Valganciclovir Tablets USP 450 mg, a therapeutic equivalent generic version of VALCYTE� (Valganciclovir) tablets in the US market on December�15, 2014, approved by the United States Food�& Drug Administration (USFDA).
The VALCYTE� (Valganciclovir) tablets brand had U.S. sales of approximately $440 Million MAT for the most recent twelve months ending in October 2014 according to IMS Health*.
Dr.�Reddy�s Valganciclovir tablets, USP in 450 mg is available in bottle counts of 60.
WARNING: HEMATOLOGIC TOXICITY, CARCINOGENICITY, TERATOGENICITY, AND IMPAIRMENT OF FERTILITY
See full prescribing information for complete boxed warning.
�
| � | � | � | Clinical toxicity of valganciclovir, which is metabolized to ganciclovir, includes granulocytopenia, anemia, and thrombocytopenia. |
�
| � | � | � | In animal studies, ganciclovir was carcinogenic, teratogenic, and caused aspermatogenesis. |
Disclaimer
This press release includes forward-looking statements, as defined in the U.S. Private Securities Litigation Reform Act of 1995. We have based these forward-looking statements on our current expectations and projections about future events. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially. Such factors include, but are not limited to, changes in local and global economic conditions, our ability to successfully implement our strategy, the market acceptance of and demand for our products, our growth and expansion, technological change and our exposure to market risks. By their nature, these expectations and projections are only estimates and could be materially different from actual results in the future.
About Dr.�Reddy�s
Dr.�Reddy�s Laboratories Ltd. (NYSE: RDY) is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products � Dr.�Reddy�s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Major therapeutic focus is on gastro-intestinal, cardiovascular, diabetology, oncology, pain management and anti-infective. Major markets include India, USA, Russia-CIS and Europe apart from other select geographies within Emerging Markets. For more information, log on to: www.drreddys.com
VALCYTE� is a registered trademark of�Hoffmann-La Roche Inc.
�
| * | IMS National Sales Perspectives: Retail and Non-Retail MAT October 2014 |
�
3
For more information, please contact:
�
| Investors and Financial Analysts: | �� | Media: |
| Kedar Upadhye at [email protected] /+91-40-66834297 | �� | Shilpi Lathia at [email protected]/+91-40-49002448 |
| Saunak Savla at [email protected] /+91-40-49002135 | �� | |
| Ashish Girotra (USA) at [email protected]/+1-609-375-9805 | �� | |
�
4
Dr.�Reddy�s Laboratories closes the acquisition of Habitrol� Brand from Novartis
Hyderabad, India, December�19, 2014
Dr.�Reddy�s Laboratories has announced that it has closed the acquisition of Habitrol� brand (an over-the-counter nicotine replacement therapy transdermal patch) from Novartis Consumer Health Inc. following issuance of the proposed consent order from the U.S. Federal Trade Commission (FTC) on November�26, 2014. The company had earlier entered into an asset purchase agreement with Novartis Consumer Health Inc. to acquire the title and rights of Habitrol� brand and to market the product in the U.S. market.
With this closure, the company has assumed responsibility for the product and will commence shipments of the product in the market shortly.
Disclaimer
This press release includes forward-looking statements, as defined in the U.S. Private Securities Litigation Reform Act of 1995. We have based these forward-looking statements on our current expectations and projections about future events. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially. Such factors include, but are not limited to, changes in local and global economic conditions, our ability to successfully implement our strategy, the market acceptance of and demand for our products, our growth and expansion, technological change and our exposure to market risks. By their nature, these expectations and projections are only estimates and could be materially different from actual results in the future.
About Dr.�Reddy�s
Dr.�Reddy�s Laboratories Ltd. (NYSE: RDY) is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products � Dr.�Reddy�s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Major therapeutic focus is on gastro-intestinal, cardiovascular, diabetology, oncology, pain management and anti-infective. Major markets include India, USA, Russia-CIS and Europe apart from other select geographies within Emerging Markets. For more information, log on to: www.drreddys.com
For more information, please contact:
�
| Investors and Financial Analysts: | �� | Media: |
| Kedar Upadhye at [email protected] /+91-40-66834297 | �� | Shilpi Lathia at [email protected]/+91-40-49002447 |
| Saunak Savla at [email protected] /+91-40-49002135 | �� | |
| Ashish Girotra (USA) at [email protected]/+1-609-375-9805 | �� | |
�
5
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
�
| � | � | DR. REDDY�S LABORATORIES LIMITED | ||||||
| � | � | (Registrant) | ||||||
| � | � | By: | � | /s/ Sandeep Poddar | ||||
| Date: January 6, 2015 | � | � | � | Name: | � | Sandeep Poddar | ||
| � | � | � | Title: | � | Company Secretary | |||
�
6
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Dr. Reddy's Laboratories Ltd. (DRRD:IN) (RDY) PT Lowered to INR5,700 at Goldman Sachs
- Final Week of Containing Luxury's StartEngine Crowdfunding Campaign
- Aurora Humanitarian Initiative Co-Founder Noubar Afeyan Issues Global Call To Prevent A Second Armenian Genocide
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
